Keywords
How to Cite
Abstract
Natriuretic peptides are widely known for their protective effects against the development of metabolic syndrome and cardiovascular disease. The important role of determining the levels of natriuretic peptides in the diagnosis, assessment of severity, prognosis and effectiveness of treatment of heart failure has been proven in many studies and noted in clinical guidelines worldwide. Visceral obesity reduces the production and action of natriuretic peptides, increasing the risk of heart failure and diabetes mellitus 2 type. Metabolic syndrome is present in 60% of patients with chronic heart failure, most of its components contribute to the development and progression of chronic heart failure and include obesity, hypertension, dyslipidemia, insulin resistance, impaired glucose tolerance. The prevalence of metabolic syndrome in the general population is 34% and is constantly increasing due to unhealthy diet, sedentary lifestyle and chronic stress. The prevalence of chronic heart failure is increasing rapidly in all industrialized countries, affecting 2% of adults and 10% of the elderly. Therefore, the problem of early diagnosis and treatment of metabolic syndrome and chronic heart failure is very relevant nowadays. The review focuses on the pathophysiological relationships between natriuretic peptides, heart failure and metabolic syndrome, and the approaches to the correction of natriuretic peptides’ metabolism.
References
Bajaj, N.S., Patel, N., Prabhu, S.D., Arora, G., & Wang, T.J. (2018). Effect of NT-proBNP–Guided Therapy on All-Cause Mortality in Chronic Heart Failure With Reduced Ejection Fraction. J Am Coll Cardiol, 27, 71(8), 951‒952.
Brunner-La Rocca, H., & Sanders-van Wijk, S. (2019). Natriuretic Peptides in Chronic Heart Failure. Card Fail Rev, 5(1), 44–49.
Immaculate, N., Walter, M., Higgins, C., & Li, C. (2021). Use of B-Type Natriuretic Peptide (BNP) and N-Terminal proBNP (NT-proBNP) as Diagnostic Tests in Adults With Suspected Heart FailureOnt Health Technol Assess Ser., 21(2), 1-125.
Yancy, C.W., Jessup, M., Bozkurt, B., Butler, J., & Casey, D.E. (2017). 2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure. A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Journal of the American College of Cardiology, 70, 6.
Piepoli, M.F., Hoes, A.W., Agewall, S., Albus, C., Brotons, C. et al. (2016). 2016 European Guidelines on cardiovascular disease prevention in clinical practice European Heart Journal, 37, 2315–2381.
Barrett-Connor, E. (2013). The Rancho Bernardo Study: 40 years studying why women have less heart disease than men and how diabetes modifies women’s usual cardiac protection.
Catapano, A.L., Graham, I., De Backer, G., Wiklund, O., John, M. et al. (2016). 2016 ESC/EAS Guidelines for the Management of Dyslipidaemias. European Heart Journal, 37, 2999–3058.
Brunner-La Rocca, H., Kaye, D., Woods, R., Hastings, J., & Esler, M. (2001). Effects of intravenous brain na-triuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects. J Am Coll Cardiol, 37, 5, 1221‒1227.
Januzzi, J.J., Camargo, C.A., Anwaruddin, S., Baggish, A.L., & Chen, A.A. (2005). The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol, 15, 95(8), 948‒954.
Januzzi, J.J., Chen-Tournoux, A.A., Christenson, R.H., Doros, G., & Hollander, J.E. (2018). N-Terminal Pro-B-Type Natriuretic Peptide in the Emergency Department: The ICON-RELOADED Study. J Am Coll Cardiol., 20, 71(11), 1191‒1200.
Kerkelä, R., & Ulvila, J. (2015). Natriuretic Peptides in the Regulation of Cardiovascular Physiology and Met-abolic Events. Journal of the American Heart Association, 4, 10.
Maisel, A., Duran, J., & Wettersten, N. (2018). Natriuretic Peptides in Heart Failure Atrial and B-type Natriu-retic Peptides. Heart Failure Clin, 14, 13–25.
Meems, L., & Burnett, J. (2016). Innovative Therapeutics Designer Natriuretic Peptides. JACC: Basic to trans-lational science, 1, 7.
Thawabi, M., Hawatmeh, A., Studyvin, S., Habib, H., & Shamoon, F. (2017). Cardiac troponin and outcome in decompensated heart failure with preserved ejection fraction. Cardiovasc Diagn Ther, 7, 4, 359–366.
Willeit, P., Kaptoge, S., Welsh, P., Butterworth, A.S., & Chowdhury, R. (2016). Natriuretic peptides and in-tegrated risk assessment for cardiovascular disease: an individual-participant-data meta-analysis. Lancet Diabetes Endo-crinol, 4, 10, 840‒849.
Maisel, A.S., & Daniels, L.B. (2012). Breathing Not Properly 10 Years Later: What We Have Learned and What We Still Need to Learn. Journal of the American College of Cardiology, 60, 4, 277‒282.
Januzzi, J.J., Camargo, C.A., Anwaruddin, S., Baggish, A.L., & Chen, A.A. (2005). The N-terminal Pro-BNP investigation of dyspnea in the emergency department (PRIDE) study. Am J Cardiol, 15, 95(8), 948‒954.
Jordan, J., Birkenfeld, A.L., Melander, O., & Moro, C. (2018). Natriuretic Peptides in Cardiovascular and Metabolic Crosstalk. Hypertension, 72, 270–276.
Baba, M., Yoshida, K., (2019). Applications of Natriuretic Peptides in Heart Failure and Atrial Fibrillation. Int J Mol Sci, 20(11), 2824.
McDonagh, T.A., Metra, M., Adamo, M., et al. (2021). 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure. Eur Heart J., 42(36), 3599‒3726.
Nadar, S., & Shaikh, M. (2019). Biomarkers in Routine Heart Failure Clinical Care. Card Fail Rev, 5, 1, 50–56.
Kang, S., Park, J.J., Choi, D., Yoon, C., & Oh, I. (2015). Prognostic value of NT-proBNP in heart failure with preserved versus reduced EF. Heart, 101(23), 1881‒1888.
Fudim, M., Ambrosy, A., & Sun, J. (2018). High‐Sensitivity Troponin I in Hospitalized and Ambulatory Pa-tients with Heart Failure With Preserved Ejection Fraction: Insights From the Heart Failure Clinical Research Network. Journal of the American Heart Association, 116, 1217–1220.
Thawabi, M., Hawatmeh, A., Studyvin, S., Habib, H., & Shamoon, F. (2017). Cardiac troponin and outcome in decompensated heart failure with preserved ejection fraction. Cardiovasc Diagn Ther, 7, 4, 359–366.
Zhu, Q., Xiao, W., Bai, Y., Ye, P., & Luo, L. (2016). The prognostic value of the plasma N-terminal pro-brain natriuretic peptide level on all-cause death and major cardiovascular events in a community-based population. Clin Interv Aging, 16, 11, 245‒253.
Rudolf, H., Mügge, A., Trampisch, H.J., Scharnagl, H., März, W., & Kara, K. (2020). NT-proBNP for risk prediction of cardiovascular events and all-cause mortality: The getABI-study. Int J Cardiol Heart Vasc, 29, 100553.
Kitada, S., Kikuchi, S., Tsujino, T., Masuyama, T., & Ohte, N. (2018). The prognostic value of brain natriu-retic peptide in patients with heart failure and left ventricular ejection fraction higher than 60%: a sub‐analysis of the J‐MELODIC study. ESC Heart Fail, 5(1), 36–45.
Omland, T., Sabatine, M.S., Jablonski, K.A., Rice, M.M., Hsia, J. et al. (2007). Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial. J Am Coll Cardiol, 50(3), 205‒14.
Liu, H., Cao, Y., Jin, J., Guo, Y., Zhu, C. et al. (2021). Prognostic value of NT-proBNP in patients with chronic coronary syndrome and normal left ventricular systolic function according to glucose status: a prospective co-hort study. Cardiovascular Diabetology, 20, 84.
Souza, T., Cerqueira, A.M., Suerdieck, J.G., de Sá, N.C., Sodré, G.S. et al. (2020). Prognostic Value of NT-proBNP versus Killip Classification in Patients with Acute Coronary Syndromes. Arq Bras Cardiol, 114(4), 666‒672.
He, W., Jiang, L., Chen, Y., Liu, Y., Chen, P., Duan, C., et al. (2021). The association of baseline N-terminal pro-B-type natriuretic peptide with short and long-term prognosis following percutaneous coronary intervention in non-ST segment elevation acute coronary syndrome with multivessel coronary artery disease: a retrospective cohort study. BMC Cardiovascular Disorders, 21, 202.
Wang, L., Cong, H., Zhang, J., Hu, Y., & Li, X. (2021). Prognostic Significance of Preprocedural N-Terminal Pro-B-Type Natriuretic Peptide Assessment in Diabetic Patients with Multivessel Coronary Disease Undergoing Revas-cularization. Front. Cardiovasc. Med.
Zile, M.R., Claggett, B.L., Prescott, M.F., McMurra, J., & Packer, M. (2016). Prognostic Implications of Changes in N-Terminal Pro-B-Type Natriuretic Peptide in Patients with Heart Failure. J Am Coll Cardiol, 68(22), 2425‒2436.
Salah, K., Stienen, S., Pinto, Y.M., Eurlings, L.W., & Metra, M. (2019). Prognosis and NT-proBNP in heart failure patients with preserved versus reduced ejection fraction. Heart, 105(15), 1182–1189.
Savoia, C., Volpe, M., Alonzo, A., Rossi, C., & Rubattu, S. (2009). Natriuretic peptides and cardiovascular damage in the metabolic syndrome: molecular mechanisms and clinical implications. Clin Sci (Lond), 118(4), 231‒240.
Santhekadur, P.K., Kumar, D.P., Seneshaw, M., Mirshahi F., & Sanyal, A.J. (2017). The multifaceted role of natriuretic peptides in metabolic syndrome. Biomed Pharmacother, 92, 826‒835.
Moyes, A.J., & Hobbs, A.J. (2019). C-Type Natriuretic Peptide: A Multifaceted Paracrine Regulator in the Heart and Vasculature. Int J Mol Sci, 20(9), 2281.
Nakao, K., Kuwahara, K., Nishikimi, T., Nakagawa, Y., & Kinoshita, H. (2017). Endothelium-Derived C-Type Natriuretic Peptide Contributes to Blood Pressure Regulation by Maintaining Endothelial Integrity. Hyperten-sion, 69, 286–296.
Gruden, G., Landi, A., & Bruno, G. (2014). Natriuretic Peptides, Heart, and Adipose Tissue: New Findings and Future Developments for Diabetes Research. Diabetes Care, 37(11), 2899‒2908.
Spannella, F., Giulietti F., Bordicchia M., Burnett J.C., & Sarzani R. (2019). Association Between Cardiac Natriuretic Peptides and Lipid Profile: a Systematic Review and Meta-Analysis. Scientific Reports, 9, 19178.
Birkenfeld, A., Budziarek, P., & Boschmann, M. (2008). Atrial Natriuretic Peptide Induces Postprandial Lipid Oxidation in Humans. Diabetes, 57, 12, 3199–3204.
Miyashita, K., Itoh, H., & Tsujimoto, H. (2009). Natriuretic Peptides/cGMP/cGMP-Dependent Protein Kinase Cascades Promote Muscle Mitochondrial Biogenesis and Prevent Obesity. Diabetes, 58, 12, 2880‒2892.
Tauscher, S., Nakagawa, H., & Völker, K. (2015). Role of atrial natriuretic peptide (ANP) in the regulation of insulin secretion and vitality of pancreatic ß cells. BMC Pharmacol Toxicol, 16, 1.
Undank, S., Kaiser, J., & Sikimic, J. (2017). Atrial Natriuretic Peptide Affects Stimulus-Secretion Coupling of Pancreatic β-Cells. Diabetes, 66, 11, 2840‒2848.
Welsh, P., & McMurray, J. (2012). B-type natriuretic peptide and glycaemia: an emerging cardiometabolic pathway? Diabetologia, 55, 1240–1243.
Coué, M., & Moro, C. (2015). Natriuretic peptide control of energy balance and glucose homeostasis. Bio-chimie, 124, 84‒91.
Maisel, A., Duran, J., & Wettersten, N. (2018). Natriuretic Peptides in Heart Failure Atrial and B-type Natriu-retic Peptides. Heart Failure Clin, 14, 13–25.
Sarzani, R., Spannella, F., & Giulietti, F. (2017). Cardiac Natriuretic Peptides, Hypertension and Cardiovascu-lar Risk. High Blood Press Cardiovasc Prev, 24, 2, 115–126.
Neeland, I., Winders, B., Ayers, & C., Das, S. (2013). Higher Natriuretic Peptide Levels Associate with a Fa-vorable Adipose Tissue Distribution Profile. JACC, 62, 8, 752–760.
Ramos, H., Birkenfeld, A., & de Bold, A. (2015). Cardiac natriuretic peptides and obesity: perspectives from an endocrinologist and a cardiologist. Endocrine Connection, 4, 25‒36.
De Almeida, J., Alves, C., & de Abreu, L. (2012). Involvement of the atrial natriuretic peptide in cardiovascu-lar pathophysiology and its relationship with exercise. Int Arch Med, 5, 4.
Khan, A., Cheng, S., & Magnusson, M. (2011). Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies. J Clin Endocrinol Metab, 96, 10, 3242-3249.
Malachias, M.V., Jhund, P.S., & Claggett, B.L. (2020). NT‐proBNP by Itself Predicts Death and Cardiovascu-lar Events in High‐Risk Patients with Type 2 Diabetes Mellitus. Journal of the American Heart Association, 9, 017462.
Coué, M., & Moro, C. (2015). Natriuretic peptide control of energy balance and glucose homeostasis. Bio-chimie, 124, 84‒91.
Villar, R., Becerra, A., & Alameda, C. (2012). Effects of acute hyperglycaemia on ANP levels in diabetic pa-tients. Endocrine Abstracts, 29, 677.
Cleasby, M. (2015). ANP-ing Up Diabetes: Impaired Natriuretic Peptide Action in Muscle Forms a Mechanis-tic Link Between Obesity and Diabetes. Diabetes, 64, 12, 3978‒3980.
Everett, B., Cook, N., & Chasman, D. A. (2013). Prospective Evaluation of B-type Natriuretic Peptide Con-centrations and the Risk of Type 2 Diabetes in Women. Clin Chem, 59, 3, 557–565.
Heinisch, B., Vila, G., & Resl, M. (2012). B-type natriuretic peptide (BNP) affects the initial response to in-travenous glucose: a randomised placebo-controlled cross-over study in healthy men. Diabetologia, 55, 1400–1405.
Khan, A., Cheng, S., & Magnusson, M. (2011). Cardiac natriuretic peptides, obesity, and insulin resistance: evidence from two community-based studies. J Clin Endocrinol Metab, 96, 10, 3242‒3249.
Rubattu, S., & Volpe, M. (2019). Natriuretic Peptides in the Cardiovascular System: Multifaceted Roles in Physiology, Pathology and Therapeutics. Int J Mol Sci, 20, 16, 3991.
"Inter Collegas" is an open access journal: all articles are published in open access without an embargo period, under the terms of the CC BY-NC-SA (Creative Commons Attribution ‒ Noncommercial ‒ Share Alike) license; the content is available to all readers without registration from the moment of its publication. Electronic copies of the archive of journals are placed in the repositories of the KhNMU and V.I. Vernadsky National Library of Ukraine.
Copyright Agreement
1. This Agreement on the transfer of rights to use the work from the Co-authors to the publisher (hereinafter the Agreement) is concluded between all the Co-authors of the work, represented by the Corresponding Author, and Kharkiv National Medical University (hereinafter the University), represented by an authorized representative of the Editorial Board of scientific journals (hereinafter the Editorial Board).
2. This Agreement is an accession agreement within the meaning of clause 1 of Article 634 of the Civil Code of Ukraine: that is, a contract, "the terms of which are established by one of the parties in forms or other standard forms, which can be concluded only by joining the other party to the proposed contract as a whole. The other party cannot offer its terms of the contract." The party that established the terms of this contract is the University.
3. If there is more than one author, the authors choose the Corresponding Author, who communicates with the Editorial Board on his own behalf and on behalf of all Co-authors regarding the publication of a written work of a scientific nature (article or review, hereinafter referred to as the Work).
4. The contract begins from the moment of submission of the manuscript of the Work by the Corresponding Author to the Editorial Board, which confirms the following:
4.1. all Co-authors of the Work are familiar with and agree with its content, at all stages of reviewing and editing the manuscript and the existence of the published Work;
4.2. all Co-authors of the Work are familiar with and agree to the terms of this Agreement.
5. The published Work is in electronic form in public access on the websites of the University and any websites and electronic databases in which the Work is posted by the University and is available to readers under the terms of the "Creative Commons" license (Attribution NonCommercial Sharealike 4.0 International)" or more free licenses "Creative Commons 4.0".
6. The Corresponding Author transfers, and the University receives, the non-exclusive property right to use the Work by placing the latter on the University's websites for the entire term of copyright. The University participates in the creation of the final version of the Work by reviewing and editing the manuscript of the article or review provided to the Editorial Board by the Corresponding Author, translating the Work into any languages. For the participation of the University in the finalization of the Work, the Co-authors agree to pay the invoice issued to them by the University, if such payment is provided by the University. The size and procedure of such payment are not the subject of this contract.
7. The University has the right to reproduce the Work or its parts in electronic and printed forms, to make copies, permanent archival storage of the Work, distribution of the Work on the Internet, repositories, scientometric databases, commercial networks, including for monetary compensation from third parties.
8. The co-authors guarantee that the manuscript of the Work does not use works whose copyright belongs to third parties.
9. The authors of the Work guarantee that at the time of submission of the manuscript of the Work to the Editorial Board, the property rights to the Work belong only to them, neither in whole nor in part have they been transferred to anyone (not alienated), they are not the subject of a lien, litigation or claims by third parties.
10. The Work may not be posted on the University's website if it violates a person's right to the privacy of his personal and family life, harms public order and health.
11. The work may be withdrawn by the Editorial Board from the University websites, libraries and electronic databases where it was placed by the Editorial Board, in cases of detection of violations of the ethics of the authors and researchers, without any compensation for the losses of the Co-authors. At the time of submission of the manuscript to the Editorial Board and all stages of its editing and review, the manuscript must not have already been published or submitted to other editorial offices.
12. The right transferred under this Agreement extends to the territory of Ukraine and foreign countries.
13. The rights of Co-authors include the requirement to indicate their names on all copies of the Work or during any public use or public mention of the Work; the requirement to preserve the integrity of the Work; legal opposition to any distortion or other encroachment on the Work, which may harm the honor and reputation of the Co-authors.
14. Co-authors have the right to control their personal non-property rights by familiarizing themselves with the text (content) and form of the Work before its publication on the University's website, when transferring it to a printing company for reproduction or when using the Work in other ways.
15. The Co-authors, in addition to the property rights not transferred under this Agreement and taking into account the non-exclusive nature of the rights transferred under this Agreement, retain the property rights to finalize the Work and to use certain parts of the Work in other works created by the Co-authors.
16. The Co-authors are obliged to notify the Editorial Board of all errors in the Work, discovered by them independently after the publication of the Work, and to take all measures to eliminate such errors as soon as possible.
17. The University undertakes to indicate the names of the Co-authors on all copies of the Work during any public use of the Work. The list of Co-authors may be shortened according to the rules for the formation of bibliographic descriptions determined by the University or third parties.
18. The University undertakes not to violate the integrity of the Work, to agree with the Corresponding Author on all changes made to the Work during processing and editing.
19. In case of violation of their obligations under this Agreement, its parties bear the responsibility defined by this Agreement and the current legislation of Ukraine. All disputes under the Agreement are resolved through negotiations, and if the negotiations do not resolve the dispute – in the courts of the city of Kharkiv.
20. The parties are not responsible for the violation of their obligations under this Agreement, if it occurred through no fault of theirs. The party is considered innocent if it proves that it has taken all measures dependent on it for the proper fulfillment of the obligation.
21. The Co-authors are responsible for the truthfulness of the facts, quotes, references to legislative and regulatory acts, other official documentation, the scientific validity of the Work, all types of responsibility to third parties who have claimed their rights to the Work. The co-authors reimburse the University for all costs caused by claims of third parties for infringement of copyright and other rights to the Work, as well as additional material costs related to the elimination of identified defects.